The acyclic ligands H 4 C3octapa and p-SCNBn-H 4 C3octapa were synthesized for the first time, using nosyl protection chemistry. These new ligands were compared to the previously studied ligands H 4 octapa and p-SCN-Bn-H 4 octapa to determine the extent to which the addition of a single carbon atom to the backbone of the ligand would affect metal coordination, complex stability, and, ultimately, utility for in vivo radiopharmaceutical applications. Although only a single carbon atom was added to H 4 C3octapa and the metal donor atoms and denticity were not changed, the solution chemistry and radiochemistry properties were drastically altered, highlighting the importance of careful ligand design and radiometal−ligand matching. 
■ INTRODUCTION
In recent years, radiometal-based radiopharmaceuticals have become increasingly appreciated for their potential in diagnostic and therapeutic medicine. 1−10 The modular and versatile nature of these systems allows for a continually increasing number of routinely produced radiometals to be harnessed for single photon emission computed tomography (SPECT), positron emission tomography (PET), and therapy (e.g., Auger electron, β − , α).
1−10 Radiometal-based radiopharmaceuticals are typically broken down into several modules and can be assembled in many permutations for a high degree of customization: the targeting vector (e.g., peptide, antibody, nanoparticle) is selected for site-specific delivery to a chosen biological target or compartment; the bifunctional chelator (BFC) is selected for optimal stability and radiolabeling properties with the chosen radiometal; the bioconjugation method is selected based on the reactivity and functional groups available on the bifunctional chelator and targeting vector; and, finally, the radiometal is selected for its decay characteristics. 1−9 Even subtle changes to the ligand structure, site of conjugation, and donor arms of ligands can cause drastic changes to their radiolabeling properties and the stability of their radiometal complexes. These ligand alterations can include the addition of functional groups to allow for conjugation with targeting vectors (e.g., p-benzyl-isothiocya-nate, maleimide, activated esters), changes to ligand donor arms and ligand denticity (e.g., peptide coupling to a carboxylate donor arm), and changing ligand donor types (e.g., changing primary amines to secondary amines, or methylenephosphonates for carboxylates), and the effects of these changes on radiolabeling and stability properties can be significant. 1−10 The difference in stability and radiolabeling kinetics between acyclic and macrocyclic ligands is often significant, as macrocycles provide a degree of preorganization of the metal binding cavity, which provides a strong entropic incentive for metal complexation, although typically at the cost of slow reaction kinetics. 11−13 There are a number of competent and wellstudied bifunctional chelators available for use; however, none are without shortcomings, and for purposes ranging from enhancing radiolabeling kinetics to enhancing kinetic inertness and in vivo stability, development of new bifunctional chelators is an important field of study. 3, 7, 8, 14, 15 The literature is rich with examples of how small changes in cavity size, chelate-ring size, bifunctionalization site, and coordination environment can make drastic changes in the stability of radiometal complexes. This article discusses differences in binding of two structurally similar acyclic ligands to the specific radiometals 111 In and 177 Lu. Although each radiometal ion has unique aqueous chemistry properties, and the difference between macrocyclic and acyclic ligands is substantial, examples using different metal ions and both acyclic and macrocyclic ligands will be discussed. As an example of cavity size effects, the chemistry of the positron-emitting radiometal ion 64 Cu 2+ with the widely used, macrocyclic chelators DOTA and NOTA provides an excellent illustration of the importance of the careful consideration of ligand properties (Chart 1). The denticity and cavity size of the macrocycle NOTA is smaller than that of DOTA (6 vs 8 maximum denticity) and therefore is a better fit for radiometals such as 64 Cu and 68 Ga, resulting in increased stability and inertness of these metal complex. 16−21 A common site of bifunctional derivatization of DOTA is one of its 4 carboxylic acid arms, which effectively masks one of the carboxylic acid chelating arms, effectively dropping the denticity from 8 to 7 (although the carbonyl can still coordinate to metal ions, albeit weakly). 22 This is a good example of how changing ligand donor groups can effect the stability of radiometal complexes, as this functionalization of DOTA causes a noted decrease in the in vitro and in vivo stability of its radiometal complexes with isotopes like 111 In (DO3A, Chart 1). 22 An example of how ligand isomers can affect stability is the acyclic ligand CHX-DTPA, where 4 possible ligand isomers can be synthesized, with CHX-A″-DTPA being the most stable isomer by a substantial margin (Chart 1). 23, 24 Another example of how subtle changes in ligand donor groups can effect stability are macrocyclic TE2A derivatives (cyclam-based, Chart 1), which undergo remarkable changes in radiolabeling and stability properties as a result of simply alkylating the two secondary amine groups of TE2A to form tertiary amines, either with methyl groups (MM/DM-TE2A) or an ethylene bridge (CB-TE2A). 25, 26 The result of these TE2A modifications are that a large improvement in the in vitro and in vivo stability of the 64 Cu complexes of MM/DM-TE2A is observed, relative to that of TE2A. 25, 26 An example of the predilection certain radiometals have for 5-or 6-membered chelate rings can be found when comparing the stability of cyclam-and cyclen-based ligands with the Cu 2+ isotope 64 Cu. 25, 27 The inclusion of some 6-membered chelate rings (cyclam-based) in ligands such as TETA and CB-TE2A yields some improvements in stability in vitro and in vivo when compared to that for ligands that contain only 5-membered chelate rings (cyclen-based) such as DOTA and CB-DO2A. 25 These findings suggest that 6-membered chelate rings may work well with Cu 2+ , at least when comparing the specific ligand scaffolds of cyclen and cyclam. 27 In this specific example, it appears that copper prefers some 6-membered chelate rings (TETA) to strictly 5-membered chelate rings (DOTA); however, the smaller macrocycle NOTA forms more stable complexes with Cu 2+ than TETA while forming only 5-membered chelate rings. 16, 17 Conversely, previous work in our laboratory on the chelation of Ga 3+ with the ligand H 2 dedpa suggested a better fit for Ga 3+ , which is even smaller than Cu 2+ (62 vs 73 pm for CN = 6, respectively), with 5-membered chelate rings over 6-membered chelate rings. 15 The discussion of which chelate ring-size is the best fit and the most stable for large metal ions such as In 3+ , Lu 3+ , and Y 3+ is less opaque. DOTA has been shown to be superior to TETA for large metal ions like In 3+ , Lu
3+
, and Y
, suggesting that the optimal stability of large metal ions is achieved when using 5-membered chelate rings, which supports this work comparing H 4 octapa to H 4 C3octapa. 2, 3, 7, 8 These examples demonstrate the lack of clarity for the preference of some metal ions between 5-and 6-membered chelate rings, providing a compelling reason to perform further studies on the subject.
We have previously published work on the acyclic ligand H 4 octapa and the bifunctional derivative p-SCN-Bn-H 4 octapa, which showed very promising ambient temperature radiolabeling performance and in vitro and in vivo stability with 111 In and 177 Lu. This study was performed by conjugating p-SCNBn-H 4 octapa to an antibody (trastuzumab) as a proof-ofprinciple targeting vector for HER2/neu-expressing ovarian cancer cells (SKOV3).
14,28 Largely due to their exceptional specificity and affinity, antibodies are extremely useful targeting vectors for the delivery of radioactive isotopes to cancerous tissues. 29, 13 Antibodies also possess long biological half-lives (∼2 to 3 weeks in vivo), which makes them excellent vehicles for proof-of-principle studies of new bifunctional ligands in which stability in vitro and in vivo must be studied for several days/weeks. 13 The isotopes 111 In and 177 Lu are widely used in both research and clinical settings, with 111 In being a cyclotronproduced radiometal ( 111 Cd(p,n) 111 In) for SPECT imaging (t 1/2 ∼ 2.8 days) and Auger electron therapy and 177 Lu being a reactor-produced therapeutic radiometal ( 176 Lu(n,γ) 177 Lu) that emits β − particles as well as γ-rays (t 1/2 ∼ 6.6 days).
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To further evaluate the impact of ligand structure changes on radiolabeling efficiency and stability, we have synthesized the novel derivative of H 4 octapa, H 4 C3octapa, modified with only a single additional carbon atom (1,3-propylenediamine vs 1,2-ethylenediamine backbone) (Chart 1). Herein, we report the synthesis, characterization, In 3+ /Lu 3+ metal complexation, density functional theory (DFT) structure prediction, potentiometric titrations to determine thermodynamic stability constants, and 111 In/ 177 Lu radiolabeling and in vitro blood serum stability of the new ligand H 4 C3octapa and its bifunctional derivative p-SCN-Bn-H 4 C3octapa (Chart 1). In this study, we have conjugated both the new p-SCN-Bn-H 4 C3octapa and the previously studied p-SCN-Bn-H 4 octapa to the HER2/neu-targeted antibody trastuzumab and directly compared their properties. The purpose of this work was to determine the extent to which a small structural change of the ligand, which, importantly, does not change the ligand denticity or metal coordinating groups, may affect radiolabeling performance and most importantly the stability of radiometal complexes. Our laboratory has been studying new acyclic chelators based on the pyridinecarboxylate scaffold for several years now, and this work aims to expand upon our understanding of ligand design and radiometal−ligand matching (Chart 1). 14,15,31−37 ■ EXPERIMENTAL SECTION Materials and Methods. All solvents and reagents were purchased from commercial suppliers (Sigma-Aldrich, St. Louis, MO; TCI America, Portland, OR; Fisher Scientific, Waltham, MA) and were used as received unless otherwise indicated. The bifunctional chelator p-SCN-Bn-H 4 octapa was synthesized as previously described. 28 DMSO used for chelator stock solutions was of molecular biology grade (>99.9%: Sigma, D8418). 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid para-benzylisothiocyanate (p-SCN-Bn-DOTA) was purchased from Macrocyclics, Inc. (Dallas, TX). Methyl-6-bromomethylpicolinate was synthesized according to a literature protocol.
14 Water used was ultrapure (18.2 MΩ cm −1 at 25°C, Milli-Q, Millipore, Billerica, MA). The analytical thin-layer chromatography (TLC) plates were aluminum-backed ultrapure silica gel (Siliaplate, 60 Å pore size, 250 μM plate thickness, Silicycle, Quebec, QC). Flash column silica gel was provided by Silicycle (Siliaflash Irregular Silica Gels F60, 60 Å pore size, 40−63 mm particle size, Silicycle, Quebec, QC). Automated column chromatography was performed using a Teledyne Isco (Lincoln, NE) CombiFlash R f automated system with solid load cartridges packed with flash column silica gel and RediSep R f Gold reusable normal-phase silica columns and neutral alumina columns (Teledyne Isco, Lincoln, NE).
1 H and 13 C NMR spectra were recorded on Bruker AV300, AV400, or AV600 instruments; all spectra were internally referenced to residual solvent peaks except for 13 C NMR spectra in D 2 O, which were externally referenced to a sample of CH 3 OH/D 2 O. Low-resolution mass spectrometry was performed using a Waters liquid chromatography−mass spectrometer (LC−MS) consisting of a Waters ZQ quadrupole spectrometer equipped with an ESCI electrospray/chemical ionization ion source and a Waters 2695 HPLC system (Waters, Milford, MA). High-resolution electrospray− ionization mass spectrometry (ESI−MS) was performed on a Waters Micromass LCT time-of-flight instrument. Microanalyses for C, H, and N were performed on a Carlo Erba EA 1108 elemental analyzer. The HPLC system used for purification of nonradioactive compounds consisted of a semipreparative reverse-phase C18 Phenomenex synergi hydro-RP (80 Å pore size, 250 × 21.2 mm, Phenomenex, Torrance, CA) column connected to a Waters 600 controller, a Waters 2487 dual-wavelength absorbance detector, and a Waters delta 600 pump. 177 Lu(chelate) analysis was performed using an HPLC system comprised of a Shimadzu SPD-20A prominence UV/vis, LC-20AB prominence LC, a Bioscan flow-count radiation detector, and a C 18 reverse-phase column (Phenomenex Luna Analytical 250 × 4.6 mm). UV/vis measurements for determining antibody stock solution concentrations were taken on a Thermo Scientific Nanodrop 2000 spectrophotometer (Wilmington, DE). 177 LuCl 3 in 0.05 M HCl. Labeling reactions were monitored using silica-gel impregnated glass-microfiber instant thin-layer chromatography paper (iTLC-SG, Varian, Lake Forest, CA) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan Radio-TLC software (Bioscan Inc., Washington, DC). All radiolabeling chemistry was performed with ultrapure water (>18.2 MΩ cm −1 at 25°C, Milli-Q, Millipore, Billerica, MA) that had been passed through a 10 cm column of Chelex resin (BioRad Laboratories, Hercules, CA). Human blood serum (Sigma, Sera, human, aseptically filled, S7023-100mL) competition solutions were agitated at 550 rpm and held at 37°C using an Eppendorf thermomixer, and then 177 Lu(chelate) mixtures were analyzed using GE Healthcare Life Sciences PD-10 desalting columns (GE Healthcare, United Kingdom, MW < 5000 Da filter) that were conditioned by elution of 25 mL phosphate-buffered saline (PBS) before use.
177 Lu/ 111 In-immunoconugates were analyzed using iTLC as described above and purified using PD-10 desalting columns and Corning 50k MW Amicon Ultra centrifugation filters. Radioactivity in samples was measured using a Capintec CRC-15R dose calibrator (Capintec, Ramsey, NJ).
N,N′-(2-Nitrobenzenesulfonamide)-1,3-diaminopropane (1). Propylenediamine (173 μL, 2.05 mmol) was dissolved in THF (10 mL) and placed in an ice bath; then, sodium bicarbonate (∼1 g) was added, followed by slow addition of 2-nitrobenzenesulfonyl chloride (0.954 g, 4.31 mmol). The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The yellow mixture was filtered to remove sodium bicarbonate, rotary evaporated to a red oil, purified by silica chromatography (CombiFlash R f automated column system; 120 g HP silica; A: dichloromethane, isocratic elution), and dried in vacuo to yield the product (1) (2) . To a solution of 1 (0.418 g, 0.941 mmol) in dimethylformamide (10 mL, dried over molecular sieves 4 Å) were added methyl-6-bromomethyl picolinate 14 (0.476 g, 2.07 mmol) and sodium carbonate (∼1 g). The faint yellow reaction mixture was stirred at 50°C overnight, filtered to remove sodium carbonate, and concentrated in vacuo. The crude product was purified by silica chromatography (CombiFlash R f automated column system; 80 g HP silica; A: chloroform, B: methanol, 100% A to 25% B gradient) to yield the product 2 as yellow solid (98%, ∼0.685 g). 1 
. To a solution of 2 (0.685 g, 0.922 mmol) in tetrahydrofuran (10 mL) was added thiophenol (223 μL, 2.03 mmol) and potassium carbonate (excess, ∼0.4 g). The reaction mixture was stirred at 60°C for 48 h, during which time the color changed from light yellow to dark yellow. The reaction mixture was filtered with a large fritted glass filter to remove K 2 CO 3 , rinsed liberally with THF and CH 3 CN, and then concentrated to dryness in vacuo. The resulting crude yellow oil was purified by alumina chromatography (CombiFlash R f automated column system; 24 g neutral alumina; A: dichloromethane, B: methanol, 100% A to 30% B gradient) to yield 3 as yellow oil (89%, ∼0.306 g). Compound 3 was purified using neutral alumina, as it demonstrates an abnormally high affinity for silica and requires the use of ammonium hydroxide and >20% methanol to be eluted, resulting in partial methyl-ester deprotection and dissolving of some silica. 1 (8) . This synthesis was adapted from a literature preparation. 38 Sodium ethoxide (3.47 g, 50.9 mmol) was added to ethanol (100 mL), followed by slow addition of diethyl malonate (14.1 mL, 14.8 g, 92.6 mmol) and then 4-nitrobenzyl bromide (10.0 g, 46.3 mmol). The dark orange reaction mixture was heated to reflux overnight, and it was observed that a fine white precipitate formed. The volume of the reaction mixture was reduced to 20 mL, it was placed in the freezer for several hours to encourage maximum precipitation, and then the shiny white solid was isolated via suction filtration. The procedure was repeated, reducing the volume to ∼5−10 mL and then placing in the freezer to recover more product. The white solid was filtered and rinsed with cold ethanol to isolate pure 8 (3.76 g, 12.7 mmol, ∼27% (9) . Compound 8 (3.52 g, 11.9 mmol) was dissolved in methanol (125 mL) to form a clear and colorless mixture and was then placed in an ice/salt bath. After cooling, ammonia gas was purged through the reaction vessel for ∼10 min with vigorous stirring to allow for NH 3 (g) saturation. After NH 3 (g) saturation, the reaction mixture turned clear yellow. The ammonia gas flow was ceased, and the reaction vessel was sealed with a rubber septum and then allowed to stir in the ice bath overnight. While stirring overnight, the ice bath melted, and the reaction mixture warmed to ambient temperature. After stirring overnight, a precipitate was observed to have formed, and the reaction mixture was a yellow/ orange suspension. The reaction mixture was allowed to stir at ambient temperature for a second night (∼36 h total). The precipitate was filtered out, washed with methanol followed by boiling acetonitrile, and then dried in vacuo. The product (9) was isolated as yellow solid (2.34 g, 9.86 mmol, ∼83%). 1,3-Diamino-2-(4-nitrobenzyl)propane Dihydrochloride (2-(p-nitrobenzyl)-1,3-propylenediamine) (10). Compound 9 (1.99 g, 8.40 mmol) was added to a two-necked round-bottomed flask under argon gas, and an addition funnel was attached. Borane stabilized in THF (BH 3 ·THF, 1 M, 15 mL) was added, and the reaction mixture was heated to reflux under argon gas for 20 h. The reaction mixture was clear yellow with solid precipitate on the sides of the flask. The reaction mixture was removed from heat, ∼30 mL of concentrated HCl (12 M) was added slowly, and the mixture heated to reflux for ∼1 h. The reaction mixture was reduced to dryness in vacuo, and then ∼40 mL of NaOH (6 M) was added. The aqueous phase was extracted with dichloromethane (5 × 30 mL), and the light yellow organic extractions were pooled and dried over magnesium sulfate, filtered, and reduced to dryness in vacuo. The product was then suspended in ∼20 mL of ethanol, concentrated HCl was added (∼3 mL, 12 M), and the flask placed in the freezer. A light yellow precipitate formed, which was filtered out, washed with dichloromethane, and dried in vacuo to isolate pure 10 (0.544 g, 2.39 mmol, ∼28%). (11) . Compound 10 (205 mg, 0.979 mmol) was dissolved in THF (10 mL), and the reaction mixture placed in an ice bath. Sodium bicarbonate (∼1 g) was added, followed by the slow addition of 2-nitrobenzenesulfonyl chloride (445 mg, 2.01 mmol). The reaction mixture was stirred overnight at ambient temperature. The yellow/orange mixture was filtered to remove sodium bicarbonate, rotary evaporated to a red oil, and purified by silica chromatography (CombiFlash R f automated column system; 40 g HP silica; A: hexanes, B: ethyl acetate, 100% A to 100% B gradient), and dried in vacuo to yield 11 as off-white solid (77%, ∼439 mg).
1 H NMR (300 MHz, acetone-d 6 (12) . To a solution of 11 (195 mg, 0.336 mmol) in dimethylformamide (5 mL, dried over molecular sieves 4 Å) were added tert-butylbromoacetate (109 μL, 0.740 mmol) and sodium carbonate (∼400 mg). The yellow reaction mixture was stirred at 50°C overnight, filtered to remove sodium carbonate, and concentrated in vacuo. The crude product was purified by silica chromatography (CombiFlash R f automated column system; 40 g HP silica; A: ethyl acetate, B: petroleum ether, 100% A to 100% B gradient) to yield 12 as light yellow fluffy solid (83%, ∼224 mg). (13) . To a solution of 12 (224.4 mg, 0.278 mmol) in tetrahydrofuran (5 mL) were added thiophenol (58.2 μL, 0.569 mmol) and potassium carbonate (excess, ∼0.4 g). The reaction mixture was stirred at ambient temperature for 72 h as a slow color change from light yellow to dark yellow occurred. The crude reaction mixture was filtered out with a large fritted glass filter, rinsed liberally with THF and CH 3 CN, and then concentrated to dryness in vacuo. The resulting crude yellow oil was purified by silica chromatography (CombiFlash R f automated column system; 24 g HP silica; A: dichloromethane, B: methanol, 100% A to 30% B gradient) to yield 13 as clear yellow oil (90%, ∼109 mg). (14) . To a solution of 13 (52.2 mg, 0.119 mmol) in acetonitrile (5 mL) were added methyl 6-(bromomethyl)-picolinate 14 (57.6 mg, 0.251 mmol) and sodium carbonate (∼200 mg). The reaction mixture was stirred at 60°C overnight. Sodium carbonate was removed by filtration, and the crude mixture was concentrated in vacuo. The crude oil was purified by column chromatography (CombiFlash R f automated column system; 24 g HP silica; A: dichloromethane, B: methanol, 100% A to 20% B gradient) to afford 14 as light yellow oil (95%, ∼83.6 mg). 1 (15) . Compound 14 (92.4 mg, 0.126 mmol) was dissolved in glacial acetic acid (2.5 mL) with hydrochloric acid (2.5 mL, 3 M). Palladium on carbon (10 wt %) was added, and hydrogen gas (balloon) was purged through the reaction vessel that was then sealed with a rubber septum. The reaction mixture was stirred vigorously at ambient temperature for 1 h and then filtered to remove Pd/C and washed ad libitum with methanol and hydrochloric acid (3 M). The crude reaction mixture was concentrated in vacuo, dissolved in a mixture of tetrahydrofuran/deionized water (3:1, 5 mL), LiOH (150 mg) was added, and the mixture was stirred at ambient temperature for 1 h. The crude reaction mixture was dissolved in hydrochloric acid (∼2 mL, 3 M), heated to near boiling with a heat gun to affect full tert-butyl ester deprotection, and then allowed to cool to ambient temperature. The crude reaction mixture was then mixed with thiophosgene (purchased suspended in chloroform) in ∼0.2 mL of additional chloroform (15 equiv, 144 μL, 1.88 mmol) to react overnight at ambient temperature with vigorous stirring. The reaction mixture was washed with chloroform (5 × 1 mL) by vigorous biphasic stirring, followed by removal of the organic phase using a pipet to extract excess thiophosgene. The aqueous phase was then diluted to a volume of 4.5 mL with deionized water and injected directly onto a semiprep HPLC column for purification (A: 0.1% TFA in deionized water, B: 0.1% TFA in CH 3 CN, 100% A to 60% B gradient over 40 min). p-SCN-Bn-H 4 C3octapa (15) was found in the largest peak at t R = 35 min (broad), lyophilized overnight, and was isolated as a fluffy off-white solid (53% over three steps from 15, ∼40 mg). 1 Molecular Modeling. Calculations were performed using the Gaussian 09 39 and GaussView packages. Molecular geometries and electron densities were obtained from density functional theory calculations, with the B3LYP functional employing the 6-31+G(d,p) basis set for first-and second-row elements, and the Stuttgart/Dresden and associated ECP's basis set was employed for the metals, lutetium and indium. 40, 41 Solvent (water) effects were described through a continuum approach by means of the IEF PCM as implemented in G09. The electrostatic potential was mapped onto the calculated electron density surface. The corresponding harmonic vibration frequencies were computed at the same level to characterize the geometry as a minimum.
Solution Thermodynamics. The experimental procedures and details of the apparatus closely followed our reported studies of H 2 − and [Lu(C3octapa)] − , the complex formation constant with this ligand could not be determined directly, and ligand−ligand competition using the known competitor, Na 2 H 2 EDTA, was employed. Potentiometric titrations were performed using a Metrohm Titrando 809 equipped with a Ross combination pH electrode and a Metrohm Dosino 800. Data were collected in triplicate using PC Control (version 6.0.91, Metrohm). The titration apparatus consisted of a water-jacketed glass vessel maintained at 25.0 (±0.1°C, Julabo water bath). Prior to and during the course of the titration, a blanket of nitrogen, passed through 10% NaOH to exclude any CO 2 , was maintained over the sample solution. Indium and lutetium ion solutions were prepared by dilution of the appropriate atomic absorption standard (AAS) solution. The exact amount of acid present in the indium and lutetium standard was determined by separate titrations of equimolar solutions of In 3+ or Lu 3+ and Na 2 H 2 EDTA. The amount of acid present was determined by Gran's method. 43 Calibration of the electrode was performed prior to each measurement by titrating a known amount of HCl with 0.1 M NaOH. Calibration data were analyzed by standard computer treatment provided within the program MacCalib 44 to obtain the calibration parameters E 0 . Ligand solutions were prepared 24 h in advance of titrations to allow for equilibration. Electrode equilibration times for titrations were up to 10 min for pK a titrations and up to 3 h for metal complex titrations (<0.2 mV/min drift allowed). Ligand and metal concentrations were 0.75−1.0 mM for potentiometric titrations. The data were treated with Hyperquad2008. 45 The proton dissociation constants corresponding to hydrolysis of In 3+ (aq) and Lu 3+ (aq) ions included in the calculations were taken from Baes and Mesmer. 46 The K ML value for the indium−EDTA and lutetium−EDTA complexes was taken from Martell. Values of pM were calculated under physiologically relevant conditions of pH 7.4, 10 μM ligand, and 1 μM metal. All values and errors represent the average of at least three independent experiments.
Trastuzumab Antibody Modification/Thiourea Bioconjugation. Trastuzumab (purchased commercially as Herceptin, Genentech, San Francisco, CA) was purified using centrifugal filter units with a 50 000 molecular weight cutoff (Amicon ultra centrifuge filters, Ultracel-50: regenerated cellulose, Millipore Corp., Billerica, MA) and phosphate buffered saline (PBS, pH 7.4) to remove α-α-trehalose dihydrate, L-histidine, and polysorbate 20 additives. After purification, the antibody was taken up in PBS, pH 7.4. Subsequently, 300 μL of antibody solution (150−250 μM) was combined with 100 μL of PBS (pH 8.0); the pH of the resulting solution was adjusted to 8.8−9.0 with 0.1 M Na 2 CO 3 , and 4 equiv of the p-SCN-Bn-H 4 C3octapa or p-SCN-Bn-H 4 octapa was added in 10 μL DMSO. The reactions were incubated at 37°C for 1 h, followed by centrifugal filtration to purify the resultant antibody conjugate. The final modified antibody stock solutions were stored in PBS (pH 7.4) at 4°C.
111 In-and 177 Lu-C3octapa/octapa−Trastuzumab Radiolabeling. Aliquots of H 4 C3octapa/H 4 octapa−trastuzumab immunoconjugates (∼400 μg) were transferred to 2 mL microcentrifuge tubes and made up to 1 mL of ammonium acetate buffer (pH 5.5, 200 mM), and then aliquots of 177 Lu or 111
In were added (∼2−3 mCi). The H 4 octapa−trastuzumab mixtures were allowed to radiolabel at room temperature for 30 min and then analyzed via iTLC with an eluent of 50 mM EDTA (pH 5) and confirmed reproducible values >95% RCY, with 111 In being ∼94−95% (∼2.23 mCi/mg) and 177 Lu being ∼97− 98% (∼2.52 mCi/mg) ( Figures S21−S24) . The H 4 C3octapa− trastuzumab mixtures were allowed to radiolabel at room temperature for 60 min and then analyzed via iTLC with RCY for 111 In of ∼95− 96% (∼2.25 mCi/mg) and RCY of 177 Lu of ∼8−9% (∼0.3 mCi/mg). The low radiolabeling yield for 177 Lu appears to be due to immediate transchelation of 177 Lu to the iTLC EDTA mobile phase, suggesting poor stability of the H 4 C3octapa complex. EDTA solution (30 μL, 50 mM, pH 5) was then added to the reaction mixture; the resultant radiolabeled immunoconjugates were then purified using sizeexclusion chromatography (Sephadex G-25 M, PD-10 column, 30 kDa, GE Healthcare; dead volume = 2.5 mL, eluted with 1 mL fractions of PBS, pH 7.4) and centrifugal column filtration (Amicon ultra 50k MWCO). The radiochemical purity of the final radiolabeled bioconjugate was assayed by radio-iTLC and was found to be >99% for both H 4 octapa−trastuzumab samples ( Figures S21−24) , but for 111 In-C3octapa−trastuzumab a small amount of 111 In was transchelated by the EDTA mobile phase after purification ( Figures S21−24 Lu to a ligand concentration of ∼180 μM and made up to 1 mL with NaOAc buffer (10 mM, pH 5.0). H 4 octapa, H 4 C3octapa, and DTPA were allowed to radiolabel at ambient temperature for 10 min, and DOTA was radiolabeled for 1 h at 90°C. Radiometal complexes were then evaluated using radio-HPLC to confirm quantitative radiometal coordination (linear gradient A: 0.1% TFA in H 2 O, B: CH 3 CN, 0− 80% B over 30 min). Radiolabeled ligands were then used for blood serum stability assays. Frozen human blood serum was thawed for 30 min, and 750 μL aliquots were transferred to 2.0 mL Corning centrifuge vials. Three hundred microliters of each 177 Lu(chelate) was transferred to 750 μL of blood serum along with 450 μL of PBS to a total volume of 1.5 mL (n = 3 for each ligand). The final 177 Lu-(chelate) concentration present in serum was ∼36 μM. Serum competition samples were then incubated at 37 ± 0.1°C with constant agitation (550 rpm) and analyzed via PD-10 size-exclusion column elution (filters MW < 5000 Da) at 1.5 and 24 h time points and counted using a Capintec CRC-15R dose calibrator. Aliquots of 500 μL of each serum/ 177 Lu(chelate) competition solution (n = 3) were removed from the competition vial, diluted to 2.5 mL with PBS, and counted. The diluted aliquot of serum competition mixture was loaded onto a conditioned PD-10 column. The loading volume (2.5 mL) was eluted into radioactive waste, and then an additional 3.5 mL of PBS was loaded, collected, and counted in the dose calibrator as the serumbound 177 Lu (nonchelate bound). Percent stability was reported as a percentage of 177 Lu still chelate-bound and not associated with serum proteins (MW < 5000 Da). Data is shown in Table 3 . In previous work, free radiometal ( 111 In) was loaded onto a PD10 column in the same manner as described above, and it was found that no activity was eluted.
14 Additionally, 111 In was added directly to a mixture of mouse serum, loaded onto a PD10 column, and it was found that no activity was retained on the column after elution. 14 
■ RESULTS
Synthesis and Characterization. The ligand H 4 C3octapa and its bifunctional derivative p-SCN-Bn-H 4 C3octapa were synthesized for the first time using a synthetic route similar to a recently developed method for H 4 octapa (Scheme 1). 28 Although the synthesis of p-SCN-Bn-H 4 octapa utilizes the enantiopure starting material L-4-nitrophenylalanine, for p-SCN-Bn-H 4 C3octapa a different synthesis was used, starting from diethylmalonate and 4-nitrobenzyl bromide, so that a single additional carbon atom could be inserted to obtain a symmetric propylene bridged backbone (Scheme 2). 15, 47, 14, 38 The 2-nitrobenzenesulfonamide (nosyl) amine-protecting group has made the synthesis of picolinic acid-based ligands higher yielding and more efficient. 28,42,48−53 Synthesis of H 4 C3octapa was completed in five steps with a cumulative yield of ∼44%, and p-SCN-Bn-H 4 C3octapa, in seven steps with a cumulative yield of ∼29% (not including synthesis of the backbone diamine fragment).
Following ligand synthesis and purification, portions of the pure H 4 C3octapa·4HCl·2H 2 O salt (formula determined by . The previously studied compound, p-SCN-Bn-H 4 octapa, is asymmetric and contains a single stereocenter, which results in weak nuclear magnetic resonance (NMR) spectra with complicated coupling patterns, making NMR characterization challenging. 28 In contrast, p-SCN-Bn-H 4 C3octapa contains no stereocenters and retains ∼C 2 symmetry, which results in simpler coupling patterns, easier interpretation of NMR spectra, and faster spectral acquisition ( Figures S8−S10) , despite these ligands only differing by a single backbone carbon. H 4 C3octapa forms a 6-membered chelate ring when coordinated to metal ions, whereas H 4 octapa forms only 5-membered chelate rings. It is established that 5-membered chelate rings are generally more thermodynamically favorable than 6-membered rings for large metal ions, so this small structure difference between ligands (ethylene vs propylene bridge) is expected to impact stability to an extent. 11 The metal ion complexes of H 4 octapa (Figure 2 ) display less isomerization and fluxionality than do those of H 4 C3octapa (Figure 1) − showing broad signals suggesting fluxional isomerization between multiple isomers at ambient temperature (slow on the NMR time scale), whereas [Lu(octapa)]
− shows sharp and well-resolved 1 H NMR peaks, suggesting the presence of multiple static isomers at ambient temperature.
The ethylene protons of H 4 octapa originally appear as a single multiplet at ∼3.0 ppm (Figure 2 ), but these signals in the [Lu(octapa)]
− complex appear as two broad multiplets at ∼2.0−2.5 ppm (∼50:50 integration, Figure 2 ), suggesting the presence of at least two isomers. On the basis of these observations, H 4 (Figure 1 ) that the signal arising from the central propylene-bridge −CH 2 − changed from a singlet in the free ligand at ∼1.9 ppm (integration of 2H) to two broad signals at ∼0.9 and ∼1.3 ppm (total integration of 2H, ∼50% for each peak), which show no correlation to each other in the COSY spectra (see red arrows, Figures 3 and S4) . The splitting of this 1 H NMR singlet into two broad peaks upon In 3+ coordination suggest that at least two major isomers are − (Figures 1 and 3 ), most likely due to signal averaging from a faster rate of fluxional isomerization at ambient temperature.
In addition to COSY experiments, 2D-HSQC heteronuclear single bond correlation ( 1 H− 13 C) NMR spectra were obtained, which utilized an interesting diagnostic handle to assess isomerization via the 1 J C−H correlations of the pyridine rings ( Figure 4) . As previously mentioned, the 2D-HSQC experiments were more sensitive than standard 13 C experiments, allowing for detection of 13 (Figures 1 and 5) . The HSQC spectrum of [Lu(C3octapa)]
− was poorly resolved, with 10 unique carbons being observed in the aromatic region, which corresponded to pyridine C−H carbons, suggesting the presence of at least 2 fluxional isomers in solution at ambient temperature ( Figure 5 − (red arrow, Figure 3 ) began to merge at elevated temperatures (Figure 7) , further supporting the assignment of these two signals as arising from different isomers, where coalescence from signal averaging began to occur at faster rates of fluxional interconversion at higher temperatures. At higher temperatures (e.g., 135°C in DMSO-d 6 ), a further increase in coalescence would be expected for both samples; however, D 2 O was chosen as solvent for its biological relevance.
Fluxional complexes of radiometals may ultimately be unfavorable. The rapid process of metal ion deligation−ligation by ligand donor arms, which can occur as the fluxional complex constantly rearranges and shifts between isomers in solution, could open temporary holes in the coordination sphere. When these holes in the coordination sphere occur in vivo, they may provide competing ligands such as aqua, phosphate, and serum proteins (e.g., transferrin or serum albumin) opportunities to bind to the metal ion and facilitate transchelation/demetalation. Furthermore, the presence of a well-defined, single static metal−ligand isomer (as in [In(octapa)] − ) of an acyclic metal complex would be ideal. Even having multiple static isomers of a metal−ligand complex in solution is not ideal because, due to their different structures, they may exhibit different physical properties and susceptibilities to external ligand attack. If this were the case, then these different static isomers may effectively exhibit different kinetic off-rates and therefore different in vivo stability and kinetic inertness. It is important to note that this discussion pertains to isomers formed during metal coordination by a ligand and not isomers of the ligand itself. The case of ligand isomerization is demonstrated by CHX-DTPA (Chart 1), which has 4 isomers (two pairs of diastereomers, CHX-A′-DTPA, CHX-A″-DTPA, CHX-B′-DTPA, CHX-B″-DTPA), and it was observed that the single CHX-A″-DTPA isomer was substantially more stable than the other 3 isomers. 23, 24, 54, 55 The idea of correlating the degree of metal−ligand fluxional isomerization to in vivo stability is not established. However, the increased fluxionality and number of isomers observed here for H 4 C3octapa complexes compared to the analogous H 4 octapa complexes does appear to correlate to substantially inferior radiolabeling and serum stability properties for H 4 C3octapa (vide infra). This concept may be valid only for acyclic ligands and therefore may not translate to macrocyclic complexes. For example, [In(DOTA)]
− has been observed to be fluxional at ambient temperature through 1 H NMR experiments but is remarkably stable and kinetically inert in vivo. 56, 57 The rapid interconversion between isomers of a macrocyclic metal ion complex like [In(DOTA)] − may not provide the same holes in the coordination sphere for competing ligands to access the metal center, as the metal ion remains enshrouded and protected within the macrocyclic framework during this process, making transchelation slower and less likely to occur. A thorough investigation comparing the level of fluxionality of acyclic metal complexes to their radiolabeling and stability properties would be required, which, to our knowledge, has not been adequately performed.
Acid Dissociation Constants. The pK a values of ligand donor groups can effect metal coordination and radiolabeling properties, and to further study this, we experimentally determined the acid dissociation constants (pK a ) for H 4 C3octapa by potentiometric titrations. For example, a lower pK a value for functional groups such as phenols and carboxylic acids means that those acidic protons are more easily removed (at lower pH values), which allows for metal coordination and radiolabeling at lower pH values. A difference in pK a values can be observed when comparing H 4 C3octapa to H 4 octapa. Table 1 shows the acid dissociation constants for both H 4 C3octapa and H 4 octapa, with the HL and H 2 L equilibrium quotients corresponding to the protonation of backbone nitrogen atoms (1,3-propylenediamine and 1,2-ethylenediamine, respectively). Although chemically identical, these two nitrogen atoms have significantly different pK a values, as a result of charge repulsion when the two nitrogen atoms are protonated in the H 2 L species. For H 4 octapa, the difference in pK a is 3 units between these two protonated nitrogen atoms, with the deprotonation of the first backbone-en nitrogen occurring with a pK a of 5.59(6) (H 2 L), and the second, with a pK a of 8.59(4) (HL). The explanation for this is that the two positively charged protonated nitrogen atoms (H 2 L) of the 1,2-ethylenediamine backbone of H 4 octapa are held physically close together through the ethylene bridge, creating substantial charge repulsion between them, therefore making the first deprotonation event from H 2 L to HL more favorable and more acidic with a lower pK a (5.59(6) vs 8.59 (4)). The effect of extending the two-carbon ethylene (en) bridge of H 4 octapa to a three-carbon propylene (pn) bridge for the H 4 C3octapa derivative is that this charge repulsion is decreased, therefore reducing the thermodynamic driving force for removal of the first H 2 L proton. The effect of this is that the pK a for removal of the first H 2 L 1,3-propylenediamine nitrogen proton in H 4 C3octapa is over 1 unit higher (more basic) than that for H 4 octapa, with values of 6.95(6) for H 2 L and 8.86(3) for HL (Table 1) . Table 1 showing broad signals at 25°C most likely arising from fluxional isomers and/or aqua ligand exchange at 25°C, with further broadening and coalescing being observed as the temperature was increased to 85°C in 20°C increments, suggesting fluxional isomerization between multiple isomers was increased elevated temperatures. and H 5 L). The pK a value for the first deprotonation event of the H 6 L carboxylic acid could not be determined, as the value was below the threshold of the electrode (pH < 2).
Thermodynamic Stability. In order to indirectly test the hypothesis that decreased fluxional isomerization may correlate to increased stability (with acyclic ligands), we have evaluated the thermodynamic stability of the In 3+ and Lu 3+ metal complexes of H 4 C3octapa using potentiometric titrations to determine their formation constants. The molecular formula of H 4 C3octapa was determined by elemental analysis (H 4 C3octapa·4HCl·2H 2 O), and thermodynamic formation constants for H 4 octapa were previously studied. 14, 28 The thermodynamic stability constants (log K ML ) for H 4 C3octapa with In 3+ and Lu 3+ were determined by competitive potentiometric titration experiments with EDTA, under the same experimental conditions as those previously used for H 4 octapa. 14, 28 The thermodynamic stability constants (log K ML ) for In 3+ and Lu 3+ with H 4 C3octapa were experimentally determined to be 24.6 ± 0.3 (pM = 24.0) and 18.8 ± 0.3 (pM = 18.1), respectively ( Table 2 ). The thermodynamic stability 
3.54 (7) Table 2) . 28 The reason for the large variance in DOTA-Lu 3+ stability constants is that many different methods have been used due to the very slow kinetics of DOTA for forming metal ion complexes. 28,58−60 The pM value is a condition-dependent value that is calculated from the standard thermodynamic stability constant (log K ML ), accounting for variables and conditions such as ligand basicity (pK a ), metal ion hydrolysis, pH (physiological, 7.4), and a set ligand/metal ratio (10:1). The pM (= −log[M]) is essentially the metal scavenging ability of the ligand under biologically relevant conditions; the higher the pM value, the lower the concentration of free metal ion. 61 3+ and Lu 3+ complexes of both ligands suggests they are very similar to one another, with similar charge distributions determined by the overlaid molecular electrostatic potential (MEP) polar surface area maps (Figure 8 ). 14, 28 Upon qualitative visual comparison, the structures and charge distributions are very similar between these [C3octapa] 14,28 It has been proposed by Hancock that the ideal L−M−L bond angle and ideal M−L bond length for a 6-membered L−M−L chelate ring (e.g., 1,3-propylenediamine) is 109.5°and 1.6 Å, respectively, and for a 5-membered chelate ring (e.g., 1,2-ethylenediamine), 69°and 2.5 Å, respectively, with 5-membered chelate rings being ideal for larger metal ions (e.g., In 3+ and Lu 3+ ) and 6-membered chelate rings being ideal for a small metal (the approximate size of a sp 3 -hybridized carbon). 11 These predictions are not concrete but will be compared to the DFT calculated values for H 4 octapa and H 4 C3octapa metal complexes. A selection of bond lengths and angles from DFT calculated ML complexes are shown in Table 3 .
The bond lengths for the H 4 C3octapa complexes diverge from the optimum M−L values proposed by Hancock of 1.6 Å ). Performed using the B3LYP functional employing the 6-31+G(d,p) basis set for first-and second-row elements, and the Stuttgart/Dresden and associated ECP's basis set was employed for the metals, lutetium and indium. 40, 41 Solvent (water) effects were described through a continuum approach by means of the IEF PCM as implemented in Gaussian 09.
for a 6- , respectively. An inspection of the bond lengths presented in Table 3 highlights the very symmetric nature of M−L bonds in the H 4 octapa complexes (∼C 2 symmetry) and the comparatively asymmetric bonds for the H 4 C3octapa complexes, which supports the NMR data (vide supra). The NMR spectra of the H 4 C3octapa complexes revealed lower symmetry and more fluxional species than the H 4 octapa complexes, mirroring the data from DFT-calculated structures (Table 3) . These results suggest that the H 4 octapa complexes should be more stable and inert than the analogous H 4 C3octapa complexes. Although it is interesting to compare these DFT-calculated bond lengths and angles to the ideal values proposed by Hancock, evaluating the stability of the radiometal complexes is perhaps more relevant.
Trastuzumab Antibody Conjugation, 111 In/
177
Lu Radiolabeling, and In Vitro Serum Stability. To gain further insight into their differences in stability (thermodynamic and kinetic), we conjugated the bifunctional ligand derivatives p-SCN-Bn-H 4 C3octapa and p-SCN-Bn-H 4 octapa to the antibody trastuzumab, radiolabeled the resulting ligand−antibody immunoconjugate with 111 In and 177 Lu, and evaluated their stability via their inertness to transchelation by serum proteins over a period of 5 days (vide infra). As discussed in the introduction, the boundary between large and small metal ions for the most stable fit between 5-and 6-membered chelate rings is unclear. These radiolabeling and serum stability studies aim to make this boundary clear for the radiometals 111 In and 177 Lu. NMR studies, thermodynamic formation constants, and DFT structure analysis have suggested that H 4 octapa is a superior ligand to H 4 C3octapa for the large metal ions In 3+ and Lu
3+
, and that the addition of a single carbon to the structure of H 4 C3octapa was detrimental. Ultimately, the stability and inertness of these metal ion complexes must be evaluated in vitro and in vivo. Radiometric isotopic dilution assays for determining the number of chelates bound to each antibody were not performed, as previous experiments with p-SCN-Bn-H 4 octapa and p-SCN-Bn-DOTA found that the addition of 4 equiv. of isothiocyanate-ligand to trastuzumab would reliably conjugate ∼3 chelates per antibody. 28 Further to this point, the purpose of this study is to determine the difference in stability between ligands, and a difference of a few chelates per antibody would have a negligible, if any, effect on serum stability and dissociation rates. For studies trying to determine the maximum specific activity achievable for each ligand−antibody conjugate, however, the number of chelates per antibody would be a crucial piece of data.
To evaluate and compare the stability of these ligands in biologically relevant media, the nonbifunctional ligands H 4 octapa and H 4 C3octapa, along with gold standard ligands DOTA and DTPA were radiolabeled with 177 Lu and incubated in human blood serum as a transchelation challenge. The amount of 177 Lu transchelated from ligands to serum proteins was measured at 1.5 and 24 h using PD10 size-exclusion columns. The results summarized in Table 2 reveal that the stability of H 4 octapa, H 4 C3octapa, and DOTA in human serum was nearly identical during a 24 h period, with DTPA having slightly lower stability. These results are observed to diverge from the serum stability values obtained for the same ligands but as bifunctional derivatives conjugated to the antibody trastuzumab (vide infra).
Although the results summarized in Table 4 suggest that the 177 Lu complexes of H 4 C3octapa and H 4 octapa possess identical stability against serum transchelation, a much more relevant experiment is to evaluate their stability when attached to a targeting vector like trastuzumab. The practical difficulty with this approach is that bifunctional ligands are typically much more difficult to synthesize, so for early screening of new ligands, the nonbifunctional derivatives are often more expedient to use. Despite convenience, a more biologically relevant model system was evaluated by conjugating the bifunctional ligands to the HER2/neu-targeting antibody In order to assay the stability of these radioimmunoconjugates under biologically relevant conditions, all four radiolabeled constructs were incubated in human serum and PBS (control) at 37°C for a period of 5 days (Figures 9 and 10) . At the end of 5 days, the stability of the 111 In-C3octapa− and 111 In-octapa−trastuzumab immunoconjugates was determined to be ∼24 and ∼91%, respectively, revealing a significant decrease in stability of the radiometal complexes of H 4 C3octapa compared to that of H 4 octapa (Figure 9 ). The 177 LuC3octapa− and 177 Lu-octapa−trastuzumab conjugates were found to be ∼4 and ∼89% stable after 5 days, respectively, showing a more drastic decrease in stability than that observed for the analogous 111 In complexes ( Figure 10 ). Although it was known that 6-membered ligand−metal chelate rings (as with H 4 C3octapa) are less favorable than 5-membered chelate rings for large metal ions (as with H 4 octapa), 11 these serum stability results prove this point more dramatically than expected.
During elution of the iTLC strips, the ligand EDTA is present in great excess (50 mM) over the small amount of radioimmunoconjugate spotted onto the iTLC strips (0.5−1 μL of serum competition mixture) and therefore transchelation during elution is possible (Figures S21−S24) . The four serum stability challenges were therefore run in both human serum and phosphate buffered saline (PBS) as a control to determine if transchelation and radiometal leaching was occurring as a result of serum proteins or because of the excess of EDTA present in the iTLC mobile phase (Figures 9 and 10 ). For the 111 In/ 177 Lu-octapa−trastuzumab samples, there was <1% difference in stability between serum and PBS solutions. The H 4 C3octapa samples demonstrated more interesting results, with the stability of 111 In-C3octapa−trastuzumab after 120 h in serum being ∼24%, but this was much higher, at ∼85%, in PBS ( Figure 9 ). This result reveals that in a solution of PBS the 111 In-C3octapa−trastuzumab immunoconjugate remains stable and that very little 111 In is transchelated by EDTA during iTLC elution, but when placed in a solution of blood serum, a substantial amount of 111 In was transchelated by serum proteins.
The stability of 177 Lu-C3octapa−trastuzumab after 5 days in PBS and serum was ∼8 and ∼4%, respectively, suggesting that the [ 177 Lu(C3octapa)] − complex is very unstable, being easily transchelated by PBS and/or the EDTA present in the iTLC mobile phase (Figure 10) . One of the reasons for the poor radiolabeling yield and specific activity of H 4 C3octapa− trastuzumab with 177 Lu was that the complex formed was very weak, with initial iTLC analyses after radiolabeling showing substantial leaching of 177 Lu from the immunoconjugate to the EDTA mobile phase (Figures S21−S24) .
The difference of a single carbon in the backbone of this ligand scaffold clearly results in a substantial decrease in stability with these radiometals. The denticity and binding In(C3octapa)−trastuzumab in both phosphate buffered saline (PBS) and human blood serum, evaluated by spotting ∼1 μCi of serum competition mixture on silica-embedded paper iTLC strips and eluting with an aqueous EDTA (50 mM, pH 5) mobile phase. Figure 10 . Stability of the immunoconjugates 177 Lu(octapa)− trastuzumab and 177 Lu(C3octapa)−trastuzumab in both phosphate buffered saline (PBS) and human blood serum, evaluated by spotting ∼1 μCi of serum competition mixture on silica-embedded paper iTLC strips and eluting with an aqueous EDTA (50 mM, pH 5) mobile phase. groups were not changed between H 4 octapa and H 4 C3octapa, demonstrating the crucial importance of chelate ring size and ligand−metal bite size/angle, reinforcing the importance of carefully matching bifunctional chelators with radiometals for imaging and therapeutic applications. 8 These results also suggest that evaluating the stability of nonbifunctional ligands with serum transchelation experiments, using PD10 sizeexclusion elution as a method of analysis, may not be a reliable method. It was found that the nonbifunctional [ 177 Lu-(C3octapa)]
− complex was very stable to serum transchelation by PD10 size-exclusion analysis but was very unstable as the bifunctional trastuzumab conjugate by iTLC analysis. This mirrors previous results where the radiometal complex [ 111 In(decapa)] 2− was found to be stable by PD10 sizeexclusion analysis, but in vivo biodistribution results suggested that it was not stable. These results suggest that in vitro serum stability analysis of nonbifunctional ligands should be investigated with a more rigorous technique like size-exclusion HPLC. It may also be the case that only experiments with bifunctional ligand derivatives should be undertaken, as the nonbifunctional ligands will generally not be used for radiopharmaceutical applications and only bifunctional chelate conjugates are of utility. The difficulty of synthesizing most bifunctional ligands could, however, make this approach time consuming and inefficient.
■ CONCLUSIONS
The ligands H 4 C3octapa and p-SCN-Bn-H 4 C3octapa were synthesized for the first time, using nosyl protection chemistry, for comparison to the previously studied ligands H 4 octapa and p-SCN-Bn-H 4 octapa. The purpose of this work was to determine whether addition of a single carbon atom to the backbone of these ligand scaffolds would effect metal/ radiometal chelation and stability. The In 3+ and Lu 3+ complexes of H 4 C3octapa were synthesized, studied by NMR spectroscopy, DFT structure analysis, and potentiometric titrations, and compared to the analogous H 4 − complexes, with a 5-member chelate ring being formed between the N,N′-ethylene backbone and the metal centers yielding very symmetric structures. In contrast, the [In(C3octapa)]
− and [Lu(C3octapa)] − complexes were much less symmetric, with a 6-membered chelate ring being formed between the N,N′-propylene backbone and the metal centers, supporting the NMR spectral analysis that these complexes are less symmetric and rigid than the analogous H 4 octapa complexes. Potentiometric titrations were performed to determine the formation constants (log K ML , pM), which found the thermodynamic stability to be ∼2 orders of magnitude lower for the In 3+ and Lu 3+ complexes of H 4 C3octapa when compared to that of the analogous complexes of the H 4 octapa ligand. The bifunctional ligands p-SCN-Bn-H 4 C3octapa and p-SCN-Bn-H 4 octapa were conjugated to the HER2/neu targeting antibody trastuzumab and radiolabeled with 111 In and 177 Lu, and their radiochemical yields and serum stability were directly compared. It was observed that the H 4 C3octapa−trastuzumab conjugates displayed inferior radiochemistry properties to that of H 4 octapa− trastuzumab, with radiochemical yields and serum stability being substantially worse. Over a 5 day stability challenge experiment in blood serum, 111 In-octapa− and 111 In-C3octapa− trastuzumab immunoconjugates were determined to be ∼91 and ∼24% stable, respectively, and 177 Lu-octapa− and 177 LuC3octapa−trastuzumab, ∼89 and ∼4% stable, respectively. Although only a single carbon atom was added to H 4 C3octapa and the metal donor atoms and denticity were not changed, the solution chemistry and radiochemistry properties were drastically altered, highlighting the importance of careful ligand design and radiometal−ligand matching when selecting a bifunctional chelator to conjugate to targeting vectors for radiopharmaceutical applications. The exact boundary between what is considered to be small and large metal ion radii for 5/6-membered chelate ring preference is still unclear. This work further suggests that large metal ions such as In 3+ and Lu 
